ஒப்பந்த எண் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Johnson & Johnson Joins World Health Organization in Efforts to Prevent Spread of Ebola in West Africa News provided by Share this article Up to 200,000 Johnson & Johnson Ebola vaccine regimens will be made available as part of a WHO early access clinical program now underway in Sierra Leone Company s Ebola vaccine regimen also receives Prequalification from the WHO The Johnson & Johnson vaccine regimen is designed to be used proactively to induce immunity against Ebola in adults and children NEW BRUNSWICK, N.J., May 13, 2021 /PRNewswire/ Johnson & Johnson (NYSE: JNJ) (the Company) today announced the World Health Organization (WHO) and the government of Sierra Leone have begun administering the Company s Ebola vaccine regimen as part of a WHO early access clinical program aimed at preventing further spread of Ebola in West Africa. The vaccine regimen, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) in collaboration with Bavarian Nordic A/S,

Democratic republic of the congoSierra leoneRepublic of rwandaPaul stoffelsLeone kambiaRuxandra draghia akliRinda ubuzimaInserm transfertPrnewswire johnsonWhoearly access clinical programWalter reed army institute of researchNational institute of allergyMinistry of healthEuropean federation of pharmaceutical industriesCompany ebolaInnovative medicines initiative